Table 1 Characteristics of patients with irinotecan-based HIPEC
Patient | Previous syst. CTx | Previous syst. OX | Recurrent PM | Rationale for irinotecan-based HIPEC |
|---|---|---|---|---|
Patient 1 | yes | yes | yes | Oxaliplatin-associated peripheral neuropathy |
Patient 2 | yes | yes | no | 2ndline irinotecan-based systemic chemothera-py after disease progression |
Patient 3 | yes | no | no | Systemic irinotecan-based chemotherapy with response |
Patient 4 | yes | yes | no | Systemic irinotecan-based chemotherapy with response |
Patient 5 | yes | no | no | Systemic irinotecan-based chemotherapy with response |
Patient 6 | yes | no | no | Systemic irinotecan-based chemotherapy with response |
Patient 7 | yes | no | no | Systemic irinotecan-based chemotherapy with response |
Patient 8 | yes | yes | no | Oxaliplatin-associated peripheral neuropathy |
Patient 9 | yes | no | no | Systemic irinotecan-based chemotherapy with response |
Patient 10 | yes | yes | no | Progressive disease under oxaliplatin-based systemic chemotherapy |
Patient 11 | yes | yes | yes | Progressive disease under oxaliplatin-based systemic chemotherapy |
Patient 12 | yes | no | no | Systemic irinotecan-based chemotherapy with response |